Amylyx Pharmaceuticals, Inc. cash flow to debt ratio of -2.07K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Amylyx Pharmaceuticals, Inc.'s free cash flow has increased -26.41% from $-167.80M last year to $-123.48M, signaling increasing performance

Amylyx Pharmaceuticals, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Amylyx Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.02 today, signaling weakened financials

Amylyx Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Amylyx Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Amylyx Pharmaceuticals, Inc.'s profit margin has increased (-100.00%) in the last year from -345.36% to 0.00%, signaling increasing performance

Amylyx Pharmaceuticals, Inc.'s short-term assets of $323.67M exceed its short-term liabilities of $22.69M

Amylyx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Amylyx Pharmaceuticals, Inc.'s return on equity of -55.69%, is lower than 15.00%, indicating bad performance

Amylyx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Amylyx Pharmaceuticals, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Amylyx Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Amylyx Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Amylyx Pharmaceuticals, Inc.'s yearly earnings has increased -52.03% since last year from $-301.74M to $-144.74M, signaling increasing performance

Amylyx Pharmaceuticals, Inc.'s yearly revenue has decreased -100.00% since last year from $87.37M to $0.00, signaling decreasing performance

ROIC -57.13% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Amylyx Pharmaceuticals, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Amylyx Pharmaceuticals, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Amylyx Pharmaceuticals, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Amylyx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Amylyx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Amylyx Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Amylyx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Amylyx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Amylyx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Amylyx Pharmaceuticals, Inc. has a price-to-book ratio of 7.37x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Amylyx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue